TRAIL and immunity: more than a license to kill tumor cells

被引：12

作者：

Corazza, N ^{[1
]}

Brumatti, G ^{[1
]}

Schaer, C ^{[1
]}

Cima, I ^{[1
]}

Wasem, C ^{[1
]}

Brunner, T ^{[1
]}

机构：

[1] Univ Bern, Inst Pathol, Div Immunopathol, CH-3010 Bern, Switzerland

来源：

CELL DEATH AND DIFFERENTIATION | 2004年 / 11卷 / Suppl 2期

关键词：

D O I：

10.1038/sj.cdd.4401542

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The continuously growing family of structurally related proteins of the tumor necrosis factor (TNF) family has received enormous scientific attention due to their important role in the regulation of cell activation, survival death and many other physiological and pathophysiological events (reviewed in Locksley et al.1). In this News and Commentary, we will focus on the only recently recognized and appreciated role of TNF-related apoptosis-inducing ligand (TRAIL) in regulating various physiological and pathophysiological processes involving immune cells. © 2004, Nature Publishing Group. All rights reserved.

引用

页码：S122 / S125

页数：4

共 40 条

[11] NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy [J].

Hayakawa, Y ;

Screpanti, V ;

Yagita, H ;

Grandien, A ;

Ljunggren, HG ;

Smyth, MJ ;

Chambers, BJ .

JOURNAL OF IMMUNOLOGY, 2004, 172 (01) :123-129

[12] CD95 ligand - death factor and costimulatory molecule? [J].

Janssen, O ;

Qian, J ;

Linkermann, A ;

Kabelitz, D .

CELL DEATH AND DIFFERENTIATION, 2003, 10 (11) :1215-1225

[13] Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL) [J].

Kayagaki, N ;

Yamaguchi, N ;

Abe, M ;

Hirose, S ;

Shirai, T ;

Okumura, K ;

Yagita, H .

CELLULAR IMMUNOLOGY, 2002, 219 (02) :82-91

[14] Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice [J].

Lamhamedi-Cherradi, SE ;

Zheng, SJ ;

Maguschak, KA ;

Peschon, J ;

Chen, YH .

NATURE IMMUNOLOGY, 2003, 4 (03) :255-260

[15] Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes [J].

Lamhamedi-Cherradi, SE ;

Zheng, SJ ;

Tisch, RM ;

Chen, YH .

DIABETES, 2003, 52 (09) :2274-2278

[16] TRAIL: A mechanism of tumor surveillance in an immune privileged site [J].

Lee, HO ;

Herndon, JM ;

Barreiro, R ;

Griffith, TS ;

Ferguson, TA .

JOURNAL OF IMMUNOLOGY, 2002, 169 (09) :4739-4744

[17]

Leverkus M, 2000, BLOOD, V96, P2628

[18] The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase [J].

Lin, Y ;

Devin, A ;

Cook, A ;

Keane, MM ;

Kelliher, M ;

Lipkowitz, S ;

Liu, ZG .

MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (18) :6638-6645

[19] CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced [J].

Liu, ZG ;

Xu, X ;

Hsu, HC ;

Tousson, A ;

Yang, PA ;

Wu, Q ;

Liu, CR ;

Yu, SH ;

Zhang, HG ;

Mountz, JD .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (09) :1332-1341

[20] The TNF and TNF receptor superfamilies: Integrating mammalian biology [J].

Locksley, RM ;

Killeen, N ;

Lenardo, MJ .

CELL, 2001, 104 (04) :487-501

← 1 2 3 4 →